A range of new options have been listed for trading beginning April 16th, featuring notable companies and ETFs. Among these, Avalo Therapeutics (AVTX, Financial) stands out as it becomes available for options trading. This move provides investors with additional opportunities to engage with the biopharmaceutical firm known for its innovative treatment developments.
Joining Avalo Therapeutics in this options listing are GRANITESHARES 2X LONG DELL DAILY ETF (DLLL), Angion Biomedica Corp (ELTX), and ISHARES ESG AWARE MSCI USA SMALL-CAP ETF (ESML). These listings offer diverse investment strategies, catering to various risk appetites and market interests.
Additionally, options are now available for Selecta Biosciences Inc (RNAC), ToroCorp (TORO), and TVARDI THERAPEUTICS INC (TVRD), further expanding the investment landscape for traders seeking exposure to niche sectors in the biotech and small-cap markets.
In contrast, options for Cara Therapeutics (CARA) have been delisted as of April 16th, potentially impacting investors who currently hold or were planning to engage with this stock through options trading. This shift in options availability highlights the ever-evolving nature of financial markets and the importance for investors to stay informed about such changes.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Avalo Therapeutics Inc (AVTX, Financial) is $32.00 with a high estimate of $48.00 and a low estimate of $18.00. The average target implies an upside of 553.06% from the current price of $4.90. More detailed estimate data can be found on the Avalo Therapeutics Inc (AVTX) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Avalo Therapeutics Inc's (AVTX, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Avalo Therapeutics Inc (AVTX, Financial) in one year is $0.07, suggesting a downside of 98.57% from the current price of $4.9. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Avalo Therapeutics Inc (AVTX) Summary page.
